Following the judgment of the Technology and Construction Court (TCC) in BAE Systems Pensions Funds v Royal and Sun Alliance Insurance plc and others in July, it appears that a potential dispute as to coverage is not a blocker to an insurer being joined into proceedings under the Third Parties (Rights Against Insurers) Act 2010. … Continue reading Disputing rights against insurers
At the start of July, the Solicitors Regulation Authority (SRA) announced plans to change its indemnity insurance rules to make it easier for firms to switch their regulator for the purposes of professional indemnity insurance. The aim of this change, which follows a period of consultation, is to improve competition in the market, whilst ensuring … Continue reading Run-off cover: practical implications of SRA’s planned changes to indemnity insurance rules
Gladwin v Bogescu is a low value road traffic accident claim. It recently became a case of interest when the High Court allowed the defendant’s appeal against the decision of the lower court to grant relief from sanctions for late service of witness evidence.
The Law Society believes the legal sector of England and Wales underpins the UK economy. At the time of writing, a period of political uncertainty, together with Brexit negotiations becoming the priority of government, seem likely to scupper the Law Society’s vision for law and justice becoming a reality during the life of this Parliament.
Fraud is estimated to cost the insurance industry over £1.5 billion a year. The fraud itself can range from the exaggeration of a genuine claim, the falsifying of all or part of a claim or the deliberate falsification or omission of information in order to obtain less expensive cover. The insurance industry invests heavily in … Continue reading Can artificial intelligence (AI) prevent insurance fraud?
The High Court’s recent decision in the recent case of Ackerman v Thornhill and others is noteworthy in the context of disclosure and settlement litigation.
The decision in Astex Therapeutics Ltd v AstraZeneca is notable in the context of disclosure and on how legal and litigation privilege are interpreted.